ACADIA Pharmaceuticals Inc.

NASDAQ:ACAD

Biotechnology

Healthcare
$17.83 -0.60%

-$0.13 today

Market cap
$3.08B
Beta
0.83
P/E (TTM)
9.7
EPS (TTM)
$2.20
52W Low $19.69High $28.35

Volume 1.89M

Average 1.66M

ACAD Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

ACADIA Pharmaceuticals Inc.NASDAQ: ACAD

Selling, General & Admin · Q3 FY2026 · quarter ended Sep 2026

Selling, general & admin grows, but more slowly than its trailing trend

Q3 FY2026 selling, general & admin of $159.2M rose 19.3% year over year, behind the +23.5% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 0.7% from the prior quarter. Over 3 fiscal years it compounded at +14.1% a year.

Context

  • Selling, general & admin amounted to 51.2% of revenue in FY2025, up 0.2 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 14 analysts of $795.85M (+45.0%) for the fiscal year ending Dec 2026, a step up from the +12.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$159.2M-0.7% QoQ
Last fiscal yearDec 2025
$548.89M+12.4% YoY
LTMSep 2026
$646.09M+23.5% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+19.3%+44.8%+25.5 pp
1 year+12.4%+45.0%+32.6 pp
3-year CAGR+14.1%+22.0%+7.8 pp
5-year CAGR+15.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
548.89M USD
Year-over-year change
+12.4%
4-year CAGR
+8.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How ACAD compares with its peers on the latest reported figures

  • ACAD's LTM Sep 2026 selling, general & admin of $646.09M is the 2nd highest of the 11 companies compared; the peer median is $35.95M.
  • Its year-over-year change of +23.5% is the 6th highest of 10, against a peer median of +37.9%.
  • Selling, general & admin amounts to 53.7% of revenue for ACAD, versus a peer median of 117.7%.
ACAD Competitors Peer median
Selling, General & Admin for ACAD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$712.67M +55.0%+53.0%91.8%
ACADACADIA Pharmaceuticals Inc.LTM Sep 2026$646.09M +23.5%+14.1%53.7%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$256.23M +54.0%+20.4%117.7%
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026$117.61M +115.1%-0.3%—
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$55.57M -17.1%+24.5%—
MPLTMapLight Therapeutics, Inc.LTM Mar 2026$37.63M +164.2%+95.7%—
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$34.27M +37.9%+181.0%171.4%
ANROAlto Neuroscience, Inc.LTM Mar 2026$21.89M -3.6%+59.0%—
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$18.21M —+110.6%—
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$17.4M +18.2%+41.6%—
AVXLAnavex Life Sciences Corp.LTM Dec 2025$12.8M +10.2%+1.9%—
Peer median (excluding ACAD) $35.95M+37.9%+47.3%117.7%

Competitors are the stored peer set for ACAD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue484.15M517.24M726.44M957.8M1.07B
Cost of Revenue19.14M10.17M45.73M81.84M89M
Gross Profit465M507.07M680.71M875.96M982.51M
Gross Margin96.0%98.0%93.7%91.5%91.7%
Research & Development239.42M361.58M351.62M303.25M328.8M
Selling, General & Admin396.03M369.09M402.47M488.43M548.89M
Operating Expenses635.44M730.67M754.09M645.16M877.7M
Depreciation & Amortization3.34M2.03M5.55M15.88M11.76M
EBITDA(164.18M)(211.42M)(45.48M)100.16M150.66M
EBITDA Margin-33.9%-40.9%-6.3%10.5%14.1%
Operating Income(170.44M)(223.6M)(73.38M)230.79M104.81M
Operating Margin-35.2%-43.2%-10.1%24.1%9.8%
Interest Income591K6.61M17.23M25.46M31.72M
Interest Expense00000
Other Income / Expenses2.92M10.15M22.34M27.28M34.09M
Income Before Tax(167.52M)(213.44M)(51.04M)258.08M138.9M
Pre-Tax Margin-34.6%-41.3%-7.0%26.9%13.0%
Income Tax Expense351K2.53M10.25M31.62M(252.1M)
Net Income(167.87M)(215.98M)(61.29M)226.45M391M
Net Margin-34.7%-41.8%-8.4%23.6%36.5%
EPS (Basic)(1.05)(1.34)(0.37)1.372.32
EPS (Diluted)(1.05)(1.34)(0.37)1.362.29
Weighted Avg Shares160.49M161.68M163.82M165.72M169.34M
Weighted Avg Shares (Diluted)160.49M161.68M163.82M166.36M171.36M

ACADIA Pharmaceuticals Inc.

NASDAQ:ACAD

Intrinsic Alpha fair value

Locked

Current Price

$17.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.